NDAORALTABLET
Approved
Oct 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
CASODEX (bicalutamide) by ANI Pharmaceuticals is androgen receptor antagonists [moa]. First approved in 1995.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CASODEX (bicalutamide) is an oral androgen receptor antagonist approved in 1995 for prostate cancer. It works by blocking androgen signaling in prostate cancer cells, slowing tumor growth and progression. The drug is primarily used in combination with luteinizing hormone-releasing hormone (LHRH) agonists for advanced prostate cancer.
$0.381MPart D
LOE ApproachingProduct is in late-stage maturity with limited Part D market presence (86 claims, $381K annually), indicating a contracted commercial footprint requiring defensive positioning strategy.
Mechanism of Action
Androgen Receptor Antagonists
Pharmacologic Class:
Androgen Receptor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer
Started Aug 2026
56 enrolled
Prostate Cancer
An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT Treatment
Started Jul 2026
800 enrolled
Non-metastatic Castration-resistant Prostate Cancer
Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
Started Apr 2024
53 enrolled
Triple Negative Breast Neoplasms
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
Started Apr 2019
30 enrolled
Breast Neoplasm FemaleBreast CancerBreast Carcinoma+1 more
Ribociclib and Bicalutamide in AR+ TNBC
Started May 2018
37 enrolled
Triple Negative Breast Cancer
Worked on CASODEX at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.